Interferon beta-1a

Generic Name: Interferon beta-1a

Brand Names: Avonex, Rebif

Drug Type: Biotech

CAS Number: 145258-61-3

Unique Ingredient Identifier: XRO4566Q4R

Background: Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.

Indication: For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum

Associated Conditions: Relapsing Multiple Sclerosis (RMS)

Clinical Trials

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Phase 3

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod
Drug: Interferon beta-1a
Drug: Placebo capsule
Drug: Placebo i.m. injection

First Posted Date: 2013-07-04

Last Posted Date: 2025-05-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 240

Registration Number: NCT01892722

Locations: 🇺🇸
AMO Corporation, Tallahassee, Florida, United States
🇺🇸
UAB Childrens Hospital Harbor Center Neurology Dept, Birmingham, Alabama, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 9 locations

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: BIIB033
Other: Placebo
Drug: Avonex

First Posted Date: 2013-05-29

Last Posted Date: 2017-05-03

Lead Sponsor: Biogen

Target Recruit Count: 419

Registration Number: NCT01864148

Locations: 🇺🇸
OMRF Multiple Sclerosis Center of Excellence, Oklahoma City, Oklahoma, United States
🇨🇦
Research Site, Montreal, Quebec, Canada
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 65 locations

Avonex®: Safety, Blood Levels and Effects

Phase 1

Completed

Conditions: Multiple Sclerosis (MS)

First Posted Date: 2013-05-27

Last Posted Date: 2013-05-27

Lead Sponsor: Trio Medicines Ltd.

Target Recruit Count: 77

Registration Number: NCT01863069

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

Phase 4

Completed

Conditions: Multiple Sclerosis
Relapsing-Remitting

Interventions: Drug: Rebif®

First Posted Date: 2013-02-13

Last Posted Date: 2017-08-24

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 93

Registration Number: NCT01791244

Locations: 🇸🇪
Research Site, Örnsköldsvik, Sweden
🇩🇪
Please contact the Merck Communications Service for Recruiting locations, Darmstadt, Germany
🇸🇪
Research site, Ängelholm, Sweden

Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Interferon beta-1a

First Posted Date: 2013-01-11

Last Posted Date: 2016-05-04

Lead Sponsor: Biocad

Target Recruit Count: 32

Registration Number: NCT01766024

Locations: 🇷🇺
City Mariin Hospital, St. Petersburg, Russian Federation

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis

Phase 2

Withdrawn

Conditions: Relapsing Remitting Multiple Sclerosis

Interventions: Drug: RNS60 125 ml
Drug: RNS60 250 ml
Drug: Interferon beta 1a

First Posted Date: 2012-10-25

Last Posted Date: 2016-04-06

Lead Sponsor: Revalesio Corporation

Registration Number: NCT01714089

Locations: 🇺🇸
Mt. Sinai School of Medicine, New York, New York, United States

Assessing Tolerability of Avonex Intramuscular Injections

Not Applicable

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Avonex

First Posted Date: 2012-07-16

Last Posted Date: 2016-02-01

Lead Sponsor: Trinity Health Of New England

Target Recruit Count: 20

Registration Number: NCT01641120

Locations: 🇺🇸
The Mandell Center for Multiple Sclerosis, Hartford, Connecticut, United States

Impact of Disease Modifying Therapies (DMTs) and Associated Support Services in Relapsing Multiple Sclerosis (RMS) Patients

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Rebif

First Posted Date: 2012-05-17

Last Posted Date: 2015-05-29

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 545

Registration Number: NCT01601119

Locations: 🇬🇧
Please contact the, Merck KGaA Communication Center for locations, United Kingdom

A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Avonex

First Posted Date: 2011-08-12

Last Posted Date: 2011-11-04

Lead Sponsor: Biogen

Target Recruit Count: 24

Registration Number: NCT01416207

Locations: 🇨🇳
Research Site, Shanghai, China

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Interferon beta-1a
Drug: Ocrelizumab
Drug: Ocrelizumab-matching placebo
Drug: Interferon beta-1a-matching placebo

First Posted Date: 2011-08-09

Last Posted Date: 2024-03-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 835

Registration Number: NCT01412333

Locations: 🇺🇸
Infinity Clinical Research, Hollywood, Florida, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
Advanced Neurosciences Research LLC, Fort Collins, Colorado, United States

and more 162 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy